Over 400 New Jersey Auctions End Tomorrow 04/25 - Bid Now Over 1650 Total Lots Up For Auction at Four Locations - MA 04/30, NJ Cleansweep 05/02, TX 05/06, NJ 05/08
On the global backdrop of a looming worldwide epidemic of liver disease associated with the alarming prevalence of obesity and Type 2 diabetes, Echosens, a high-technology company offering the FibroScan family of products, is dedicated to assessment of chronic liver disease and positioned for exponential growth.
Headquartered in Paris with offices in the greater Boston area, Echosens is recognized as a technology innovator with the resources and capabilities to further grow and scale its operations worldwide. The leadership team, including business executives with deep, global experience in medical devices, technology and business transformation, is deploying proven strategies to promote a platform of technologies.
Evolving from a single product to a technology platform With this expertise of strong leadership, Echosens is evolving from a single product company – the FibroScan technology to non-invasively assess the stiffness of the liver – to an enterprise that offers a platform of products and services designed to broaden the utilization of liver disease assessment for a greater number of providers and payers in both public and private sectors. The new senior leadership is putting strategies in place and scaling the organization appropriately to enable them to further expand market penetration beyond its already impressive global footprint in 84 countries spanning five continents FibroScan, its inaugural non-invasive technology, set the stage for the development of a robust pipeline of products and roll-out of the strong technology platform. Today, FibroScan is recognized worldwide as the reference for non-invasive liver diagnosis supported with more than 2,000 medical publications and 40 guideline recommendations.
FibroScan quantifies the stiffness of the liver via proprietary and patented technique of transient elastography, a medical imaging modality that maps the elastic properties and stiffness of soft tissue. The degree of liver tissue stiffness will give diagnostic information about the presence or status of disease, which is critically important in the diagnosis of non-alcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver.
A two-minute examination with FibroScan offers a quick estimate of a patient’s liver fat content and stiffness. It can be performed by a medical assistant in the physician’s office as part of an annual exam, and is covered by Medicare, Medicaid and most insurance plans. Rapid results and test scores are analyzed by the physician, empowering health care providers (HCPs) with data and information that they can use to refer patients to a specialist or recommend additional assessments, if needed. Wider availability of FibroScan for diagnosis and monitoring will make a critical difference in the lives of individuals who face chronic liver disease.
